Grants
Additional funding opportunities
Research Funding Opportunities
Grants Awarded for Health Sciences Research
| Title | Type | $ Amount | Activity | Investigator |
Unit |
Sponsor | Date |
|---|---|---|---|---|---|---|---|
| A Phase Ib/II Study of Leronlimab (PRO 140) Combined with Carboplatin in Patients with CCR5+ Metastatic Triple-Negative Breast Cancer (mTNBC) | Contract | $122,212.50 | Clinical Trial | Sima Ehsani Chimeh | Cancer Center Division | CytoDyn Inc. | 10/2020 |
| Phase 1 Study of VE800 and Nivolumab in Patients with Selected Types of Advanced or Metastatic Cancer | Contract | $323,394.75 | Clinical Trial | Hani Babiker | Cancer Center Division | Vedanta Biosciences, Inc. | 05/2020 |
| A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies | Contract | $277,281.00 | Clinical Trial | Abhijeet Kumar | Cancer Center Division | BeiGene, Ltd. | 06/2022 |
| A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib | Contract | $28,800.00 | Clinical Trial | Holly Pariury | Cancer Center Division | Public Health Institute | 05/2022 |
| A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First- Line Treatment of BRCA Non-Mutated Advanced... | Contract | $100,897.00 | Clinical Trial | Setsuko Chambers | Cancer Center Division | GOG Foundation, Inc. | 08/2020 |
| INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer, a Phase II Randomized Multi-center Trial With and Without APX005M, an Anti-CD40 Agonist | Contract | $70,892.00 | Clinical Trial | Aaron Scott | Cancer Center Division | University of Texas Southwestern Medical Center | 02/2022 |
| COG NCTN Network Group Operations Center | Contract | $750,000.00 | Clinical Trial | Holly Pariury | Cancer Center Division | Children's Hospital of Philadelphia | 10/2020 |
| A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis | Contract | $252,225.12 | Clinical Trial | Jeffrey Pu | Cancer Center Division | Sumitomo Dainippon Pharma Oncology | 06/2022 |
| An open label, Phase I dose-finding study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers | Contract | $723,609.00 | Clinical Trial | Aaron Scott | Cancer Center Division | Boehringer Ingelheim International GmbH (Germany) | 07/2022 |
| Children's Oncology Group NCORP Research Base | Contract | $750,000.00 | Clinical Trial | Holly Pariury | Cancer Center Division | Children's Hospital of Philadelphia | 10/2020 |
| Phase 1/1b Multicenter, Open-Label, First-in-Human Dose Escalation and Dose Expansion Study to Assess Safety and Tolerability of Orally Administered PMD-026 in Patients with Metastatic Breast Cancer w | Contract | $100,897.00 | Clinical Trial | Pavani Chalasani | Cancer Center Division | Phoenix Molecular Designs (Canada) | 02/2020 |
| A Pivotal Randomized, Open-label Study of Optune (TTFIELDS, 200khz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma | Contract | $450,303.24 | Clinical Trial | Baldassarre Stea | Cancer Center Division | Novocure GmbH (SWITZERLAND) | 06/2022 |
| A Multicenter, Phase 1/2 Study of Selinexor in Combination with Backbone Treatments or Novel Therapies in Patients with Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) | Contract | $541,268.00 | Clinical Trial | Daniel Persky | Cancer Center Division | Karyopharm Therapeutics Inc. | 05/2021 |
| Keystroke: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA) Plus Stereotactic Re-Irradiation versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma | Contract | $32,000.00 | Clinical Trial | Jared Robbins | Cancer Center Division | Radiation Therapy Oncology Group | 04/2021 |
| One Time EOY, Integrated BIQSFP AAML1031 - Echocardiogram Reports and Images | Cooperative Agreement | $1,200.00 | Clinical Trial | Holly Pariury | Cancer Center Division | Children's Hospital of Philadelphia | 04/2021 |
| A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations | Contract | $230,527.72 | Clinical Trial | Rachna Shroff | Cancer Center Division | Seagen Inc. | 03/2021 |
| A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer | Contract | $299,953.80 | Clinical Trial | Aaron Scott | Cancer Center Division | G1 Therapeutics | 05/2021 |
| Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD1-refractory/relapsed, Unresectable Stage III or IV Melanoma | Contract | $485,781.00 | Clinical Trial | Montaser Shaheen | Cancer Center Division | BioNTech (Germany) | 04/2021 |
| A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma | Contract | $1,354,476.50 | Clinical Trial | Alejandro Recio Boiles | Cancer Center Division | Mirati Therapeutics, Inc. | 03/2021 |
| ULTRA-V: Phase 2/3 Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with C | Contract | $9,880.00 | Clinical Trial | Daniel Persky | Cancer Center Division | TG Therapeutics, Inc. | 06/2022 |
| Noncoding RNA Biomarkers for Noninvasive and Early Detection of Pancreatic Cancer | Cooperative Agreement | $64,679.91 | Research | Denise Roe | Cancer Center Division | Beckman Research Institute of The City of Hope | 03/2020 |
| A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab, in Subjects with Selected Advanced or... | Contract | $336,093.00 | Clinical Trial | Rachna Shroff | Cancer Center Division | IMV Inc. (Canada) | 03/2021 |
| A Phase 3, Randomized, Open-label Study to Evaluate the Safety and Efficacy of Pembrolizumab + Lenvatinib + Chemotherapy Induction Therapy Followed by Pembrolizumab + Lenvatinib Compared with… | Contract | $500.00 | Clinical Trial | Aaron Scott | Cancer Center Division | Merck Sharp & Dohme Corp. | 02/2021 |
| A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in Combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer | Contract | $239,544.80 | Clinical Trial | Uma Goyal | Cancer Center Division | Galera Therapeutics, LLC | 05/2021 |
| Prospective Single Arm Medical Food Study to Evaluate a Standardized Nonessential Amino Acid Restriction (NEAAR) Medical Food for the Dietary Management of Metastatic Colorectal Cancer | Contract | $99,034.20 | Clinical Trial | Aaron Scott | Cancer Center Division | Faeth Therapeutics, Inc. | 05/2022 |